BioVaxys Technology Cash Flow Statement

Financials in millions CAD. Fiscal year is November - October.

Millions CAD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Apr '24 Apr 30, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021	Oct '20 Oct 31, 2020	Oct '19 Oct 31, 2019
Net Income	-5.27	-7.69	-11.73	-6.46	-1.17	-0.23
Asset Writedown & Restructuring Costs	0.5	1.45	7.4	-	-	-
Stock-Based Compensation	3.14	3.25	0.62	1.25	0.35	-
Other Operating Activities	-1.11	-0.25	0.23	-0	0.07	0.01
Change in Accounts Payable	1.31	1.8	1.98	-0.5	0.18	-0.01
Change in Other Net Operating Assets	0.97	0.39	-0.07	0.42	-0.63	0.01
Operating Cash Flow	-0.46	-1.05	-1.57	-5.29	-1.23	-0.23
Cash Acquisitions	-	-	-	-	0.04	-
Other Investing Activities	-	-	-	-	0.02	-
Investing Cash Flow	-1.06	-	-	-	0.06	-
Short-Term Debt Repaid	-	-	-	-	-	-0.05
Total Debt Repaid	-0.03	-	-	-	-	-0.05
Net Debt Issued (Repaid)	-0.03	-	-	-	-	-0.05
Issuance of Common Stock	1.68	0.92	1.13	3.78	3.33	0.51
Other Financing Activities	-	-	-0.03	-0.34	0.02	-0.01
Financing Cash Flow	1.65	0.92	1.11	3.44	3.35	0.44
Foreign Exchange Rate Adjustments	-0	-0	0.02	0.03	0.01	-
Net Cash Flow	0.13	-0.14	-0.45	-1.83	2.19	0.21
Free Cash Flow	-0.46	-1.05	-1.57	-5.29	-1.23	-0.23
Free Cash Flow Per Share	-0.00	-0.01	-0.02	-0.06	-0.04	-0.02
Levered Free Cash Flow	2.71	4.06	-0.74	-2.71	-0.06	-
Unlevered Free Cash Flow	2.71	4.06	-0.74	-2.71	-0.06	-
Change in Net Working Capital	-1.89	-2.31	-1.02	0.22	-0.22	-

Source: S&P Capital IQ. Standard template. Financial Sources.